

15th Meeting of the European Neurological Society  
18.06.2005 - 22.06.2005

Wednesday, June 22, 2005  
08:00 - 09:30

Poster Session 5

Multiple sclerosis

- High-dose interferon beta-1b (500 mcg every-other-day, subcutaneously) treatment in RR MS patients. Safety and MRI results of 1-year follow-up** P 565  
P. Barbero, A. Pipieri, E. Verdun, M. Bergui, M. Clerico, A. Ricci, L. Giordano, A. Rovera, E. Cartechini, G. Giuliani, E. Pucci, E. Montanari, L. Manneschi, L. Durelli (Orbassano, Turin, Macerata, Fidenza, I)
- Multiple sclerosis patients treated with glatiramer acetate demonstrate a reduced secretion of the cytokines TNF-alpha and IL-6** P 566  
M. Dolev, S. Miron, G. Zelig, A. Achiron (Ramat-gan, IL)
- Association of two polymorphisms in IL-1 beta and IL-1RA genes with susceptibility for multiple sclerosis** P 568  
E. Dincic, M. Zivkovic, D. Obradovic, A. Stankovic, D. Alavantic, R. Raicevic (Belgrad, RS)
- A new fatigue scale for MS – initial validation** P 569  
R.J. Mills, C.A. Young (Liverpool, GB)
- sVCAM-1 in MS patients under interferon beta treatment: a surrogate marker for therapy response?** P 570  
K. Retzlaff, B.S. Kühne, P. Frielingshaus, S. Mannes-Keil, J. Kraus, C.V. Burger, R. Reuß, M. Kaps, P. Oschmann (Giessen, Munster, D)
- Circadian rhythmicity of cytokines and cytokine receptors in the serum of MS patients** P 572  
J. Kraus, A. Kreiling, S. Mannes-Keil, K. Retzlaff, P. Oschmann (Munster, Giessen, D)
- Glatiramer acetate induces pro-apoptotic mechanisms involving Bcl-2, Bax and Cyt-c in peripheral lymphocytes from multiple sclerosis patients** P 573  
M. Ruggieri, C. Avolio, S. Scacco, C. Pica, A. Lia, G.B. Zimatore, S. Papa, P. Livrea, M. Trojano (Bari, Foggia, I)
- A randomised, placebo-controlled phase II trial of a novel oral single-agent fumarate therapy, BG00012, in patients with relapsing-remitting multiple sclerosis** P 574  
L. Kappos, D. Miller, R. Gold, E. Havrdova, C. Polman, V. Limmroth, G. O'Neill, R. Conaghan (Basle, CH; London, GB; Goettingen, D; Prague, CZ; Amsterdam, NL; Essen, D; Cambridge, USA)
- A helper dependent adenovirus efficiently delivers bioactive FGF-II to the CNS** P 575  
E. Butti, C. Porcheri, A. Bergami, E. Brambilla, A. Cattalini, A. Recchia, A. Stornaiuolo, F. Mavilio, G. Martino, R. Furlan (Milan, I)
- Immunoablation using cyclophosphamide without haematopoietic stem cell rescue for refractory multiple sclerosis** P 576  
M. Ko, G. Katsamakakis, D. Stefoski, J. Shammo, S. Gregory (Chicago, USA)
- Magnetic resonance imaging results from SENTINEL: a randomised controlled trial of natalizumab and interferon beta-1a in multiple sclerosis** P 577  
E. W. Radue, W. Stuart, P.A. Calabresi, C. Confavreux, S. Galetta, R. Rudick, F. Lublin, B. Weinstock-Guttman, D. Wynn, F. Lynn, M. Panzara, A. Sandrock for the SENTINEL Investigators
- The efficacy of natalizumab add-on therapy in patients with relapsing multiple sclerosis: subgroup analyses of SENTINEL** P 578  
W. Stuart, P.A. Calabresi, C. Confavreux, S. Galetta, E.W. Radue, R. Rudick, F. Lublin, B. Weinstock-Guttman, D. Wynn, F. Lynn, M. Panzara, A. Sandrock for the SENTINEL Investigators
- The effect of natalizumab on brain atrophy in patients with relapsing multiple sclerosis: 2-year results from the AFFIRM study** P 579  
E. Fisher, P. O'Connor, E. Havrdova, M. Hutchinson, L. Kappos, D. Miller, J.T. Phillips, C. Polman, F. Lublin, G. Giovannoni, A. Wajgt, R. Rudick, F. Lynn, M. Toal, M. Panzara, A. Sandrock for the AFFIRM Investigators

